Niruriside 

Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC₅₀ of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection^[1].

Niruriside (260 μM; 6 days post-infection, plus 4 h XTT incubation) does not protect CEM-SS cells from acute HIV-1 RF infection at concentrations up to 260 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

770.73

C₃₈H₄₂O₁₇

173268-90-1

O=C(O[C@@H]1[C@@H](O)[C@H](COC(/C=C/C2=CC=CC=C2)=O)O[C@@]1(O[C@@H]3[C@H](OC(C)=O)[C@@H](O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O3)COC(C)=O)/C=C/C4=CC=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Qian-Cutrone J, et al. Niruriside, a new HIV REV/RRE binding inhibitor from Phyllanthus niruri. J Nat Prod. 1996;59(2):196-199.  [Content Brief]